To order this 350+page report, which features 140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
TheUSD 12 billion (by 2030) financial opportunity within the next generationimmune checkpoint modulators market has been analyzed across the followingsegments:
§ Target DiseaseIndication
- Breast Cancer
- Chronic Lymphocytic Leukemia
- Colorectal Cancer
- Head and Neck Cancer
- Lung Cancer
- Lupus Nephritis
- Melanoma
- Multiple Myeloma
- Primary Sjögren's Syndrome
- Others
§ Target ImmuneCheckpoint
- B7-H3
- CD38
- CD40
- CD47
- Others
§ Mechanism of Action
- Inhibitory
- Stimulatory
§ Therapeutic Modality
- Monoclonal Antibody
- Small Molecule
§ Type of Therapy
- Monotherapy
- Combination Therapy
§ Route ofAdministration
- Intravenous
- Subcutaneous
- Others
§ Key GeographicalRegions
- North America
- Europe
- Asia-Pacific and the Rest of the World
The NextGeneration Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030. report features thefollowing companies, which we identified to be key players in this domain:
§ Bristol Myers Squibb
§ GlaxoSmithKline
§ Incyte
§ Novartis
§ Trillium Therapeutics
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Current MarketLandscape: Clinical and Preclinical Molecules
5. Market Landscape: TherapiesTargeting Cd47
6. Market Landscape: TherapiesTargeting 4-1bb
7. Clinical Trial Analysis
8. Company Profiles: NextGeneration Inhibitors and Stimulators
9. Academic Grants Analysis
10. Partnerships andCollaborations
11. Target CompetitivenessAnalysis
12. Big Pharma Initiatives
13. Market Forecast andOpportunity Analysis
14. Concluding Remarks
15. Executive Insights
16. Appendix 1: Tabulated Data
17. Appendix 2: List ofCompanies and Organizations
To purchase a copy,please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
